Results 31 to 40 of about 117,056 (302)
Frontiers in Immunology, 2019 T-cell receptor (TCR) γδ cells are perceived as innate-like effector cells with the possibility of mediating graft-vs. -tumor (GVT) without causing graft-vs.-host disease (GVHD) in the setting of hematopoietic allogeneic stem cell transplantation (HSCT).
L. Minculescu +11 more
semanticscholar +1 more source
Frontiers in Immunology, 2019 Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that make them an attractive tool against graft- vs.-host disease (GVHD).
C. Grégoire +13 more
semanticscholar +1 more source
Frontiers in Immunology, 2018 Patients with steroid refractory gastrointestinal (GI) tract graft- vs.-host disease (GvHD) face a poor prognosis and limited therapeutic options. To accurately assess the efficacy and safety of fecal microbiota transplantation (FMT) in treating steroid ...
X. Qi +7 more
semanticscholar +1 more source
Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease
Acta Scientiarum. Health Sciences, 2016 The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients’ quality of life and mainly the reduction of mortality caused by graft-versus-
Rafaella Gabriel Maiolino +5 more
doaj +1 more source
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +1 more source
Transplantation and Cellular Therapy, 2022 BACKGROUND The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis is increasing in patients undergoing HLA-matched sibling (MSD) or unrelated (MUD) donor hematopoietic cell transplantation (HCT), but data
R. Mehta +17 more
semanticscholar +1 more source
Hematology, Transfusion and Cell Therapy, 2018 Background: Hematopoietic stem cell transplantation is a curative treatment for many patients with hematological disorders. Donor–recipient genetic disparity, especially involving the human leukocyte antigen system is a critical factor for transplant ...
Alessandra Paz +12 more
doaj +1 more source
Frontiers in Immunology, 2020 Graft-versus-host disease (GvHD) remains the second leading cause of death in allogeneic hematopoietic stem cell transplantation recipients, highlighting the need for improved preventative strategies.
Megan S. Molina +14 more
doaj +1 more source
Stem Cell Research, 2019 The immune-mediated tissue destruction of graft-vs-host disease (GvHD) remains a major barrier to greater use of hematopoietic stem cell transplantation (HSCT).
E. I. Ozay +13 more
semanticscholar +1 more source
American journal of hematology/oncology, 2018 Ruxolitinib is a promising treatment for steroid refractory graft‐vs‐host disease (GvHD). However, data concerning effects on T cells are probably involved in increased risk of opportunistic infections.
M. González Vicent +4 more
semanticscholar +1 more source